SYL1801

· Sylentis, S.A.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SYL1801, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD) [Phase 2]

See pricing